Genethera Stock Cash And Equivalents
| GTHR Stock | USD 0.0001 0.00 0.00% |
GeneThera fundamentals help investors to digest information that contributes to GeneThera's financial success or failures. It also enables traders to predict the movement of GeneThera Pink Sheet. The fundamental analysis module provides a way to measure GeneThera's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GeneThera pink sheet.
GeneThera |
GeneThera Company Cash And Equivalents Analysis
GeneThera's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current GeneThera Cash And Equivalents | 140.1 K |
Most of GeneThera's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GeneThera is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, GeneThera has 140.1 K in Cash And Equivalents. This is 99.98% lower than that of the Healthcare sector and 99.97% lower than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 99.99% higher than that of the company.
GeneThera Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GeneThera's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of GeneThera could also be used in its relative valuation, which is a method of valuing GeneThera by comparing valuation metrics of similar companies.GeneThera is currently under evaluation in cash and equivalents category among its peers.
GeneThera Fundamentals
| Return On Asset | -95.38 | |||
| Current Valuation | 1.44 M | |||
| Shares Outstanding | 35.33 M | |||
| Shares Owned By Insiders | 17.99 % | |||
| Price To Earning | (0.17) X | |||
| EBITDA | (1 M) | |||
| Net Income | (1.01 M) | |||
| Cash And Equivalents | 140.1 K | |||
| Total Debt | 806.87 K | |||
| Book Value Per Share | (0.24) X | |||
| Cash Flow From Operations | (8.57 K) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | 0.89 | |||
| Market Capitalization | 533.53 K | |||
| Total Asset | 6.3 K | |||
| Retained Earnings | (25.59 M) | |||
| Working Capital | (7.03 M) | |||
| Current Asset | 55 K | |||
| Current Liabilities | 7.08 M | |||
| Net Asset | 6.3 K |
About GeneThera Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GeneThera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneThera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneThera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.